Amfetamine controlled release (orally disintegrating tablet) - Neos Therapeutics

Drug Profile

Amfetamine controlled release (orally disintegrating tablet) - Neos Therapeutics

Alternative Names: Adzenys XR-ODT; Amfetamine polistirex; Amfetamine XR-ODT - Neos Therapeutics; Amphetamine extended-release - Neos Therapeutics; Amphetamine orally disintegrating tablet - Neos Therapeutics; Amphetamine XR-ODT - Neos Therapeutics; NT-0202

Latest Information Update: 08 May 2017

Price : $50

At a glance

  • Originator Neos Therapeutics
  • Class Amphetamines; Small molecules
  • Mechanism of Action Adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Attention-deficit hyperactivity disorder

Most Recent Events

  • 15 Mar 2017 Neos Therapeutics plans three clinical trials for Attention-deficit hyperactivity disorder (In children, 4 to less than 6 years old) in USA
  • 16 May 2016 Launched for Attention-deficit hyperactivity disorder (In adolescents, In children, In adults) in USA (PO, 3.1mg, 6.3 mg, 9.4mg, 12.5mg, 15.7mg, 18.8mg) - First global launch
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top